Lonza

Photo
12.11.2024 • News

Lonza to Expand Bioconjugation in Visp, Switzerland

Lonza, a global contract development and manufacturing organization (CDMO) for the pharmaceutical, biotech, and nutraceutical markets, announced today that it will invest in additional bioconjugation capabilities in Visp, Switzerland.

Photo
24.10.2024 • News

Lonza Extends ADC Manufacturing Collaboration with Biopharma Company

Swiss contract development and manufacturing organization (CDMO) Lonza has announced a long-term extension of its collaboration with a key global biopharmaceutical partner for the manufacture of antibody-drug conjugates (ADCs) at commercial scale. The name of the partner was not disclosed.

Photo
20.09.2024 • News

Lonza Launches Innovaform Accelerator

Lonza inaugurated its new facility at the Colmar, France site. The new Innovaform Accelerator will serve as a Center of Excellence for developing and innovating capsule-based manufacturing and delivery solutions for oral and pulmonary administration.

Photo
11.09.2024 • TopicsChemistry

The Evolution of the CDMO Industry

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.

Photo
11.09.2024 • NewsStrategy

The CDMO/CMO Report

Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and manufacturing organizations/contract manufacturing organizations (CDMOs/CMOs), including several multi-billion large-scale biomanufacturing projects. What companies are expanding, and where do these expansions stand?

Photo
09.09.2024 • News

​​Lonza Completes Expansion of Microbial Manufacturing Facility

Lonza recently announced that it has completed a planned expansion of the mid-scale microbial manufacturing facility at its Visp, Switzerland site. This multi-product facility was recently granted a GMP license, allowing cGMP manufacturing and release of biologics produced using microbial fermentation.

Photo
02.04.2024 • News

Wolfgang Wienand to Join Lonza as New CEO

Lonza has appointed Wolfgang Wienand as its new CEO. He will join the company during the summer of 2024 and succeed Albert M. Baehny, who took on the additional responsibility of interim CEO in October 2023 while the search for a permanent CEO took place.

Photo
30.01.2024 • News

Lonza and Oxford Nanopore to Collaborate on mRNA Analysis

Swiss contract development and manufacturing organization (CDMO) Lonza will collaborate with Oxford Nanopore Technologies, a UK-based company delivering a new generation of nanopore-based molecular sensing technology. The collaboration aims to cGMP validate and commercialize a first-of-its-kind novel test to accurately determine multiple critical quality attributes of mRNA products by directly sequencing both the DNA template and the messenger RNA (mRNA).

Photo
06.10.2023 • News

Lonza Increases Capacity for Antibody-Drug Conjugates at Visp, Switzerland

Swiss contract development and manufacturing organization (CDMO) Lonza is extending a long-term collaboration with an unnamed major global biopharmaceutical partner. Under the agreement, the current dedicated bioconjugation capacity will be increased fourfold by adding two new bioconjugation suites for the commercial supply of antibody-drug conjugates (ADCs) at Lonza's site in Visp, Switzerland.

Photo
13.09.2023 • TopicsStrategy

The Evolution of CDMOs

Contract development and manufacturing organizations (CDMOs) are a crucial part of the life sciences industry. Strangely, despite its current prominence, the CDMO industry is a relatively young one. There have been significant developments over its short lifespan, and it is likely that we see even more growth in the years to come.

Photo
02.06.2023 • News

Lonza Acquires ADC Specialist Synaffix

Swiss CDMO Lonza has acquired Dutch-based Synaffix, a biotech focused on ADC development. The deal comprises an initial cash injection of €100 million and up to €60 million in additional performance-based considerations. Synaffix will continue to operate under its existing name.

Photo
16.02.2023 • News

Lonza to Add Early Development Services in US

Swiss CMDO Lonza said it will expand its Early Development Services (EDS) offering into North America with a new laboratory in Cambridge, Massachusetts, set to open in May this year.

Photo
29.09.2022 • News

Lonza Completes HPAPI Expansion at Visp

Lonza has completed of the expansion of its Highly Potent API (HPAPI) multipurpose suite at the Basel-based CDMO’s alpine production site in Visp, Switzerland, adding development and manufacturing capacity for ADC payloads.

Photo
08.09.2022 • News

Lonza and Touchlight Collaborate on DNA

Lonza has entered into a collaboration with Touchlight, a biotechnology company with patented technology for producing enzymatic DNA. The enzymatic manufacturing process is said to enable GMP production at “unprecented speed, scale and purity.”

Photo
08.07.2022 • News

Lonza Builds Swiss Fill & Finish Facility

Swiss CDMO Lonza plans to build a large-scale commercial fill & finish facility in Stein. The new facility, to be located on the same campus as Lonza’s existing clinical drug product capabilities, will cost roughly 500 million Swiss francs and should be completed in 2026.

Photo
13.06.2022 • News

Samsung Biologics in $81 Million Deal with Novartis

In the their first-ever collaboration, South Korea’s Samsung Biologics and Switzerland’s Novartis have inked an initial $81 million contract manufacturing and development deal, Samsung said in a regulatory filing.

Photo
30.05.2022 • News

Lonza and Israel Biotech Fund Collaborate

Lonza and Israel Biotech Fund (IBF) have signed a framework agreement, under which the Swiss CDMO will provide advice and support for Israeli biotech companies. IBF is dedicated to investing in and developing Israel’s biotech sector.

Photo
06.04.2022 • News

Germany’s Merck Takes Lonza’s MAST Platform

Germany’s Merck has acquired Lonza’s Modular Automated Sampling Technology (MAST) platform for an undisclosed sum. The Darmstadt-based chemicals, pharmaceuticals and life science group said the deal will advance its bioprocessing portfolio and complement two earlier acquisitions in this field.

Photo
10.03.2022 • News

Lonza Completes API Expansion in China

Swiss CDMO Lonza has completed a planned laboratory expansion at its active pharmaceutical ingredients (API) manufacturing site at Nansha, China and plans to begin operation on Mar. 22.

Photo
06.12.2021 • News

Lonza and Bioqube in Biologics Pact

Swiss CDMO Lonza has agreed a five-year collaboration on the development and manufacturing of biologics and small molecules with European venture capital firm Bioqube Ventures.

Photo
19.11.2021 • News

Lonza Adds Microbial Development Facilities at Visp

CDMO Lonza is adding microbial development capabilities at its Visp, Switzerland, site. The company said the investment will support a capacity increase services targeting microbial-derived proteins. Both the expanded laboratory space and the new equipment should be in place by the end of this year.

Photo
09.11.2021 • News

Arxada and Troy Merger Would Add Muscle in Microbial Control

Swiss specialty chemicals producer Arxada, which was recently sold by CDMO Lonza to private equity funds Bain Capital and Cinven, has made its first strategic move since the separation in July. The fledgling company has announced plans to merge with Troy Corporation, a globally oriented US player in microbial control.

Photo
04.11.2021 • News

Lonza Expands Exosomes With two new Acquisitions

Swiss CDMO Lonza is making major strides to expand its position in exosome manufacturing. This week it announced two new moves. In the first, it will acquire and operate a plant at Lexington, Massachusetts, US, from Codiak BioSciences. In the second, it is acquiring a service unit in Italy.

139 more articles

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis